Genetic Variants Predicting Warfarin Sensitivity
AssigneeAcademia Sinica
InventorsYuan-Tsong Chen, Hsiang-yu Yuan, Jin-Jer Chen
Life of this patent
Estimating the term…
Abstract
We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.
Claims4
1-25. (canceled)
A method of predicting a dose range of a warfarin for a human patient, comprising:
- investigating the nucleotide at the −1639 position of the VKORC1 gene of the patient;
- determining whether the patient is warfarin sensitive or resistant based on the nucleotide at the −1639 position, wherein homozygous AA, heterozygous AG, and homozygous GG at this position indicate that the patient is warfarin sensitive, intermediate sensitive, and resistant, respectively;
- and
- predicting a warfarin dosage range based on the warfarin sensitivity/resistance of the patient.
The method of claim 1, wherein the nucleotide at the −1639 position of the VKORC1 gene is investigated by using DNA prepared from the peripheral blood of the subject.
The method of claim 1, further comprising examining the sequence of the CYP2C9 gene, and predicting a dose range for a warfarin based on the nucleotide at position −1639 of the VKORC1 gene and the sequence of the CYP2C9 gene.
Dependencies are inferred from the claim text.